BioLineRx Ltd. (BLRX) Financials

BLRX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 38.8 million 18.0 million
Dec. 31, 2025 40.9 million 17.6 million
Sept. 30, 2025 39.8 million 20.3 million
June 30, 2025 43.3 million 23.2 million

BLRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -2.3 million 78000
Dec. 31, 2025 -3.3 million 48000
Sept. 30, 2025 -2.1 million 101000
June 30, 2025 -177000 53000

BLRX Net Income

No data available :(

BLRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 17.4 million 3.4 million 1.2 million
Dec. 31, 2025 20.9 million 4.5 million 976984
Sept. 30, 2025 25.2 million 5.6 million 1.3 million
June 30, 2025 28.2 million 6.7 million 1.4 million

BLRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 4.4 million
Dec. 31, 2025 4.4 million
Sept. 30, 2025 3.9 million
June 30, 2025 3.9 million

BLRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 6000 2.5 million 858000 -
Dec. 31, 2025 25197 1.7 million 831000 -
Sept. 30, 2025 - 1.7 million 831000 5.6 million
June 30, 2025 - 2.3 million 209000 -

BLRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 477000 95000
Dec. 31, 2025 427000 84000
Sept. 30, 2025 427000 84000
June 30, 2025 304000 72000

BLRX

Price: $3.37

52 week price:
2.15
6.59

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: Israel

Volume: 323100

Ebitda: -7.1 million

Market Capitalization: 14.2 million

Links: